China Compulsory Licensing Reg Opens Door For Generics Of Patented Drugs
This article was originally published in The Pink Sheet Daily
Taking the lead from India’s recent compulsory license for Bayer’s Nexavar, China passes a compulsory license regulation that could allow generics on patented drugs.
You may also be interested in...
Bayer Says India's Natco Has No Ground For Compulsory License; Blames Lack of Drug Availability On Poor Health Infrastructure
MUMBAI - As Natco Pharma Ltd. is set to test the viability of India's highly debated compulsory licensing provisions by challenging Bayer AG's kidney and liver cancer treatment Nexavar (sorafenib), the German polymers-to-pharmaceuticals conglomerate has said that "extensive use of compulsory licenses will in the long-term undermine and threaten the patent system.
MUMBAI - In a strategic step looking to protect intellectual property rights while ensuring access to affordable life-saving medicines in developing nations, anti-HIV drugs specialist Gilead Sciences Inc. struck licensing deals July 12 with four India-based drug manufacturers - Hetero Drugs Ltd., Ranbaxy Laboratories Ltd., Strides Arcolab Ltd., and Matrix Laboratories Ltd. - for three Gilead drugs that are in late-stage clinical development
BMS Benefits From Focused Strategy, Novartis Looks To Vaccines; Abbott Tries To Educate U.S. Investors: Emerging Markets Earnings Roundup (Part 2)
Emerging markets remained a key focus of Big Pharma during first quarter earnings calls, with many highlighting exceptional growth in these markets, particularly China. Others talked at length about commercial strategy and sales force expansion, with some companies like Bristol-Myers Squibb Co. hyping the virtues of staying true to its innovative roots, while others like Novartis AG talked up the value of diversification. And Abbott Laboratories, in its continuing quest to "educate" U.S. investors about emerging markets, decided for a wholesale change in how it reports its business, although the initial reaction from at least one analyst might have caught the company off guard.